{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"92","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"96","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria.","dispersionType":"90% Confidence Interval","groups":[{"id":"OG000","title":"Phase 1 Population"},{"id":"OG001","title":"Phase II Population"},{"id":"OG002","title":"Total"}],"paramType":"NUMBER","populationDescription":"The numbers excluded 2 patients who went off study prior to start of therapy","reportingStatus":"POSTED","timeFrame":"Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.","title":"Objective Response Rate of the Drug Combination in This Patient Populations.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}